Edward Lanphier Speaking tomorrow at Regen Med & Advanced Therapies (live webcast) SGMO

Live Webcast.
Regen Med & Advanced Therapies State of the Industry Briefing
  ARM's Annual Regen Med & Advanced Therapies State of the Industry Briefing is a top-level gathering for key stakeholders in the sector - including business executives, investors, patient advocates and academic leaders - to learn more on the recent progress and outlook for the industry in the coming year. This event annualy attracts over 300 attendees and is the largest gathering specifically for regenerative medicine and advanced therapies taking place during JP Morgan week in San Francisco.

Program Agenda
8:00am - 8:20am | Program Introduction & Industry Update (pacific time, 11:00 am Eastern)
Morrie Ruffin, Managing Director, Alliance for Regenerative Medicine
Edward Lanphier, President & CEO, Sangamo BioSciences; Chairman, Alliance for Regenerative Medicine

8:20am - 9:05am | The 2016 Sector Forecast: Upcoming Clinical Data Events
This session features CEOs and senior executives from leading companies in the regenerative medicine and advanced therapies sector for a forward-looking discussion of expected clinical data events in 2016 and beyond. Panelists will address key issues related to continuing momentum in the sector as well as unique strategies and partnerships that will be required for success going forward.
Jason Kolbert, Head of Healthcare Research & Senior Managing Director, Maxim Group (co-moderator)
Jason McCarthy, Equity Research Analyst, Biotechnology, Maxim Group (co-moderator)
Silviu Itescu, Managing Director & CEO, Mesoblast
Sven Kili, VP & Head of Gene Therapy Development, GlaxoSmithKline
Gil Van Bokkelen, Chairman & CEO, Athersys
Jeffrey Walsh, COO, bluebird bio
Sue Washer, President & CEO, AGTC
9:05am - 9:50am | The Promise of Regenerative Medicine & Advanced Therapies in Oncology
This in-depth session will examine the progress of regenerative medicine and advanced therapies specifically as the field relates to the area of oncology. The panel's expert speakers will discuss a number of key hurdles on the path to commercialization including reimbursement and market access and what progress can be expected in the sector in the coming year.
Joshua Schimmer, Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
Jeffrey Abbey, President & CEO, Argos Therapeutics
Usman Azam, Global Head, Cell & Gene Therapies Unit, Novartis
André Choulika, Chairman & CEO, Cellectis
Gregg Sando, Founder & CEO, Cell Medica
9:50am | Program End